United Therapeutics Corporation $UTHR Stake Reduced by Intech Investment Management LLC

Intech Investment Management LLC trimmed its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 39.2% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 19,503 shares of the biotechnology company’s stock after selling 12,553 shares during the quarter. Intech Investment Management LLC’s holdings in United Therapeutics were worth $8,176,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently modified their holdings of UTHR. Empirical Asset Management LLC acquired a new stake in shares of United Therapeutics in the 3rd quarter worth about $981,000. TD Asset Management Inc grew its position in United Therapeutics by 5.0% in the 3rd quarter. TD Asset Management Inc now owns 138,859 shares of the biotechnology company’s stock worth $58,211,000 after purchasing an additional 6,581 shares during the last quarter. Cozad Asset Management Inc. grew its position in United Therapeutics by 13.1% in the 3rd quarter. Cozad Asset Management Inc. now owns 2,990 shares of the biotechnology company’s stock worth $1,253,000 after purchasing an additional 346 shares during the last quarter. First Financial Bankshares Inc increased its stake in shares of United Therapeutics by 48.5% in the third quarter. First Financial Bankshares Inc now owns 20,979 shares of the biotechnology company’s stock valued at $8,795,000 after purchasing an additional 6,855 shares during the period. Finally, Compound Planning Inc. bought a new stake in shares of United Therapeutics during the third quarter valued at approximately $229,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on UTHR. TD Cowen increased their price objective on United Therapeutics from $525.00 to $575.00 and gave the stock a “buy” rating in a report on Wednesday. UBS Group reiterated a “buy” rating on shares of United Therapeutics in a research report on Tuesday, February 17th. Jefferies Financial Group reissued a “buy” rating and set a $575.00 price target on shares of United Therapeutics in a report on Wednesday, November 19th. Oppenheimer lifted their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research note on Thursday. Finally, Wells Fargo & Company increased their target price on shares of United Therapeutics from $423.00 to $466.00 and gave the company an “equal weight” rating in a research report on Thursday. Nine investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, United Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $533.55.

United Therapeutics Stock Performance

UTHR opened at $503.90 on Friday. The company has a market capitalization of $22.09 billion, a PE ratio of 18.06, a P/E/G ratio of 1.79 and a beta of 0.85. The stock’s fifty day moving average is $484.38 and its 200-day moving average is $445.92. United Therapeutics Corporation has a one year low of $266.98 and a one year high of $537.19.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, beating the consensus estimate of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The business had revenue of $790.20 million during the quarter, compared to analysts’ expectations of $814.80 million. During the same quarter last year, the business posted $6.19 earnings per share. The company’s quarterly revenue was up 7.4% on a year-over-year basis. On average, equities research analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

United Therapeutics News Roundup

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Q4 outperformance and growth target — UTHR beat EPS expectations (reported strength in Tyvaso DPI sales) and management is targeting roughly a $4B revenue run‑rate by 2027 as several late‑stage product launches approach; this underpins the recent rally and longer‑term growth thesis. Read More.
• Positive Sentiment: Analysts lifting targets — Multiple firms raised price targets (examples: H.C. Wainwright, RBC, Oppenheimer), which supports further upside and institutional interest. Read More.
• Positive Sentiment: Bullish options flow — Unusually large call buying around the print suggests traders are positioning for further upside or volatility in the short term. Read More.
• Neutral Sentiment: Technical/relative strength recognition — UTHR earned a high RS rating (91), signaling market leadership but not guaranteeing direction near term. Read More.
• Neutral Sentiment: Mixed analyst views remain — while many bumped targets, some firms kept Hold/equal‑weight ratings, leaving near‑term consensus mixed. Read More.
• Negative Sentiment: Revenue missed consensus — Q4 revenue came in below Street estimates, which sparked an earlier pullback and is a reminder top‑line execution matters for the multiple. Read More.
• Negative Sentiment: Insider selling — The COO and a director disclosed multi‑lot sales in February (COO sale worth several million and director sales disclosed), which can create investor concern about near‑term insider conviction. Read More. Read More.

Insider Activity

In related news, CFO James Edgemond sold 21,000 shares of the stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $479.99, for a total transaction of $10,079,790.00. Following the completion of the sale, the chief financial officer directly owned 8,142 shares of the company’s stock, valued at $3,908,078.58. This represents a 72.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Michael Benkowitz sold 22,500 shares of the firm’s stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $479.91, for a total transaction of $10,797,975.00. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 407,954 shares of company stock valued at $197,601,528. Insiders own 10.30% of the company’s stock.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.